019 – Should a familial nonmedullary thyroid cancer indicate more aggressive therapy? Is Prospective screening necessary?

By |2017-05-30T00:04:39-03:00fevereiro 27th, 2016|Categories: 6th Thyroid Cancer, Ache, Bayer HealthCare, Cancerologia, CECATIR, Cirurgia de Cabeça e Pescoço, Cytolog, doctorUpdate, Endocrinologia e Metabologia, EUA, Growup Eventos, HOMEpage, Jennifer Sipos, LATS, Medicina Nuclear, MedTronic, Merck, Ohio, Ohio State University, Otorrinolaringologia, Patologia Clínica / Medicina Laboratorial, Radiologia e Diagnóstico por Imagem, Radioterapia, Sanofi Aventis, SBBMN, SBCCP|Tags: , , , , , , , , , , , , , , , , , , , , , , , |

Profª Jennifer Sipos - Ohio State University - EUA, Associate Professor of Medicine, Director Benign Thyroid Program Division of Endocrinology Diabetes and Metabolism The Ohio State, University School of Medicine